Edina Pallagi

Edina Pallagi

Auto-generated profile, based on publicly available information

Edina Pallagi

Institute of Pharmaceutical Technology and Regulatory Affairs, Faculty of Pharmacy, University of Szeged, Szeged, Hungary

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
Ildikó CsókaIldikó Csóka
Ildikó Csóka
RIRuba Ismail
Ruba Ismail
OLOrsolya Jójártné Laczkovich
Orsolya Jójártné Laczkovich
EPEdina Pallagi
Edina Pallagi
The translation of nanomedicines from the lab level into marketed product faces several challenges, including characterization of physicochemical properties, pharmacodynamics, pharmacokinetics, process control, biocompatibility, and nanotoxicity, scaling-up as well as reproducibility. The challenges of nanomedicine development are in connection with the different requirements from the patient (clinical and therapeutic use), industry (production), and regulatory bodies (authorization process). This paper aims at reviewing the status and regulatory aspects of nano-based drug delivery systems with a focus on the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) regulations. In addition to discussing the risks accompanied by the development of nanomedicine, the potential of following a risk-based methodology from the early stage of the R&D phase is emphasized here to ensure safety and efficacy when developing novel nano-based dosage forms. The R&D of nanomedicines is a complex and multidisciplinary approach, and there are still many challenges in their regulation and legislation. In general, the most critical considerations for nanomedicines are the product quality assessment (physicochemical characteristics, quality control, manufacturing process) and product safety assessment (pharmacokinetics, biodegradation, accumulation, and nanotoxicity). The paper presents a promising paradigm in the development and marketing authorization of nanomedicines, namely the Quality by Design (QbD) approach. Sufficient knowledge on the quality, safety, and efficacy of nanomedicines is necessary to obtain a significant focus on establishing robust, standardized methods for evaluating the critical quality attributes of nanomedicines. The QbD-based submission is highly recommended and required by the regulatory authorities, enabling a smooth clinical translation of the novel nanomedicines.

1 January 2020
Verified
Conference Paper
Closed access
Zsófia NémethZsófia Németh
Zsófia Németh
DDDorina Dobó
Dorina Dobó
EPEdina Pallagi
Edina Pallagi
ICIidikó Csóka
Iidikó Csóka

1 January 2019
Verified
Conference Paper
Closed access
Zsófia NémethZsófia Németh
Zsófia Németh
DDDorina Dobó
Dorina Dobó
EPEdina Pallagi
Edina Pallagi
ICIldikó Csóka
Ildikó Csóka

1 January 2021
Verified
Conference Paper
Closed access
Zsófia NémethZsófia Németh
Zsófia Németh
DDDorina Gabriella Dobó
Dorina Gabriella Dobó
EPEdina Pallagi
Edina Pallagi
Ildikó CsókaIldikó Csóka
Ildikó Csóka

1 January 2022
Verified
Conference Paper
Closed access
Zsófia NémethZsófia Németh
Zsófia Németh
Bence SiposBence Sipos
Bence Sipos
RJReza Semnani Jazani
Reza Semnani Jazani
DDDorina Gabriella Dobó
Dorina Gabriella Dobó
EPEdina Pallagi
Edina Pallagi
Ildikó CsókaIldikó Csóka
Ildikó Csóka